Dermatologic Manifestations of Osler-Weber-Rendu Syndrome 

  • Author: Robert A Schwartz, MD, MPH; Chief Editor: Dirk M Elston, MD   more...
 
Updated: Jun 25, 2010
 

Background

Osler-Weber-Rendu syndrome, or hereditary hemorrhagic telangiectasia (HHT), is a rare genetically determined disorder that affects blood vessels throughout the body and results in a tendency for bleeding. HHT is an autosomal dominant disorder characterized by vascular dysplasia and hemorrhage. The prognosis for the disease is good as long as bleeding is promptly recognized and adequately controlled.

Next

Pathophysiology

The pathogenesis regarding the heterogeneity of vascular malformations in patients with Osler-Weber-Rendu syndrome, or hereditary hemorrhagic telangiectasia (HHT), is obscure. A partial explanation of the pathogenesis of HHT has become possible with the identification of 2 distinct genes: the endoglin gene and the activin receptorlike kinase type I (ALK-1) gene. Endoglin and ALK-1 are type III and type I transforming growth factor-beta (TGF-B) receptors, and both are exclusively expressed on vascular endothelial cells. The binding of TGF-B to the type II TGF-B receptor on endothelial cells, which is accelerated in the presence of endoglin, results in the phosphorylation of type I TGF-B receptors, activin receptorlike kinase type 5 (ALK-5), and ALK-1. Phosphorylated ALK-5 and ALK-1 activate the downstream proteins Smad2/3 and Smad1/5, respectively.[1]

The activated Smad proteins dissociate from the type I TGF-B receptor, bind to Smad4, and enter the nucleus to transmit TGF-B signals by regulating transcription from specific gene promoters involved in angiogenesis. Therefore, a balance between the 2 signaling pathways involving ALK-5 and ALK-1 is important in determining the properties of endothelial cells during angiogenesis.

Mutations of endoglin genes and ALK-1 genes are involved in the genetic pathogenesis of HHT type 1 and HHT type 2, respectively. To date, different mutations in endoglin (at least 29) and ALK-1 (at least 17) have been found; these include missense, nonsense, frameshift, and deletion mutations. The precise mechanisms of by which these mutations elicit the vascular abnormalities in patients with HHT remain uncertain. However, the elucidation of the intracellular signal transduction mechanisms and change in targeted gene expressions by using mutant recombinant endoglin or ALK-1 proteins and knockout mice will enable physicians to understand the genetic and molecular pathogenesis of HHT and to effectively treat patients with HHT.

HHT is a disorder that is inherited in an autosomal dominant fashion,[2] although 20% of patients are unaware of a positive family history, partly because the lesions may be minimal and because 10% of patients have no episodes of bleeding. The homozygous condition probably is fatal. Histopathologic studies reveal large, irregular, thinly walled blood vessels, but the pathogenesis has not been fully established. One current theory states that systemic nevus vascular damage may not be equally expressed in all individuals with HHT. Individuals with blood group type O are affected more often, whereas males and females are affected equally. Coagulation abnormalities and increased fibrinolytic activity in the lesions may contribute to the tendency for bleeding.

Previous
Next

Epidemiology

Frequency

United States

Osler-Weber-Rendu syndrome, or hereditary hemorrhagic telangiectasia (HHT), is rare. Prevalence is 1-2 cases per 100,000 population.

International

The onsets, courses of illness, and sex distributions are the same worldwide. The condition is much more common on the Danish island of Fyn, in the Dutch Antilles, and in parts of France.

Mortality/Morbidity

Most patients with Osler-Weber-Rendu syndrome, or hereditary hemorrhagic telangiectasia (HHT), have a favorable prognosis.

  • Frequent nosebleeds and melena may result from telangiectasia in the nose and GI tract. Patients with the severe form of HHT have heavy bleeding and resultant iron-deficiency anemia. Recurrent epistaxis is observed in 50-80% of patients. In half the patients, the epistaxis becomes more serious with age, and blood transfusions are required in 10-30% of patients.
  • Pulmonary and CNS arteriovenous aneurysms may appear later in life. Patients with pulmonary AVMs and telangiectasis of the GI tract are at risk for life-threatening hemorrhage of the lungs and GI tract.
  • Other sites of bleeding may include sites in the GI tract, kidney, spleen, bladder, liver, meninges, and brain. Strokes in patients with Osler-Weber-Rendu syndrome may be either hemorrhagic or ischemic. Of patients who have pulmonary AVMs, 2% per year are estimated to have a stroke and 1% per year are estimated to develop a brain abscess. Retinal arteriovenous aneurysms occur only rarely.

Race

No racial predilection is recognized.

Sex

Males and females are affected equally.

Age

HHT may occur in children, in whom a tendency to bleed may be the first symptom.[3] However, HHT is far more common during puberty or adulthood. The syndrome most often manifests by the second or third decade of life. Pulmonary AVMs may be congenital and, therefore, diagnosed within the first year of life. The risk of GI tract bleeding increases in patients older than 50 years.

Previous
 
 
Contributor Information and Disclosures
Author

Robert A Schwartz, MD, MPH  Professor and Head, Dermatology, Professor of Pathology, Pediatrics, Medicine, and Preventive Medicine and Community Health, University of Medicine and Dentistry of New Jersey-New Jersey Medical School

Robert A Schwartz, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, and Sigma Xi

Disclosure: Nothing to disclose.

Specialty Editor Board

Mark A Crowe, MD  Assistant Clinical Instructor, Department of Medicine, Division of Dermatology, University of Washington School of Medicine

Mark A Crowe, MD is a member of the following medical societies: American Academy of Dermatology and North American Clinical Dermatologic Society

Disclosure: Nothing to disclose.

David F Butler, MD  Professor of Dermatology, Texas A&M University College of Medicine; Chair, Department of Dermatology, Director, Dermatology Residency Training Program, Scott and White Clinic, Northside Clinic

David F Butler, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, American Society for Dermatologic Surgery, American Society for MOHS Surgery, Association of Military Dermatologists, and Phi Beta Kappa

Disclosure: Nothing to disclose.

Christen M Mowad, MD  Associate Professor, Department of Dermatology, Geisinger Medical Center

Christen M Mowad, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, and Phi Beta Kappa

Disclosure: Nothing to disclose.

Glen H Crawford, MD  Assistant Clinical Professor, Department of Dermatology, University of Pennsylvania School of Medicine; Chief, Division of Dermatology, The Pennsylvania Hospital

Glen H Crawford, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, Phi Beta Kappa, and Society of USAF Flight Surgeons

Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD  Director, Department of Dermatology, Geisinger Medical Center

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

References
  1. Shovlin CL, Hughes JM, Scott J, Seidman CE, Seidman JG. Characterization of endoglin and identification of novel mutations in hereditary hemorrhagic telangiectasia. Am J Hum Genet. Jul 1997;61(1):68-79. [Medline].

  2. Grover S, Grewal RS, Verma R, Sahni H, Muralidhar R, Sinha P. Osler-Weber-Rendu syndrome: a case report with familial clustering. Indian J Dermatol Venereol Leprol. Jan-Feb 2009;75(1):100-1. [Medline].

  3. Urushihara M, Furukawa S, Ota A, Iwai A, Matsumura K, Hamada Y. Hemorrhagic telangiectasia with thrombocytopenia in a newborn infant. Pediatr Int. Dec 2000;42(6):693-5. [Medline].

  4. Jakobi P, Weiner Z, Best L, Itskovitz-Eldor J. Hereditary hemorrhagic telangiectasia with pulmonary arteriovenous malformations. Obstet Gynecol. May 2001;97(5 Pt 2):813-4. [Medline].

  5. McDonald MJ, Brophy BP, Kneebone C. Rendu-Osler-Weber syndrome: a current perspective on cerebral manifestations. J Clin Neurosci. Jul 1998;5(3):345-50. [Medline].

  6. Goodenberger DM. Visceral manifestations of hereditary hemorrhagic telangiectasia. Trans Am Clin Climatol Assoc. 2004;115:185-99. [Medline].

  7. Poisson A, Vasdev A, Brunelle F, Plauchu H, Dupuis-Girod S. Acute paraplegia due to spinal arteriovenous fistula in two patients with hereditary hemorrhagic telangiectasia. Eur J Pediatr. Feb 2009;168(2):135-9. [Medline].

  8. Garcia-Tsao G, Swanson KL. Hepatic vascular malformations in hereditary hemorrhagic telangiectasia: in search of predictors of significant disease. Hepatology. Nov 2008;48(5):1377-9. [Medline].

  9. McDonald MT, Papenberg KA, Ghosh S. A disease locus for hereditary haemorrhagic telangiectasia maps to chromosome 9q33-34. Nat Genet. Feb 1994;6(2):197-204. [Medline].

  10. De Pascalis A, Napoli M, Aprile M, Antonaci A, D'Amelio A, Buongiorno E. Gross hematuria due to acquired haemophilia in hereditary hemorrhagic telangiectasia. Blood Coagul Fibrinolysis. Oct 2008;19(7):731-3. [Medline].

  11. Manson D, Traubici J, Mei-Zahav M, MacLuskey I, John P, Stephens D. Pulmonary nodular opacities in children with hereditary hemorrhagic telangiectasia. Pediatr Radiol. Mar 2007;37(3):264-8. [Medline].

  12. Suga K, Ishikawa Y, Matsunaga N, Tanaka N, Suda H, Handa T. Liver involvement in hereditary haemorrhagic telangiectasia: assessment with 99Tcm-phytate radionuclide angiography and 123I-IMP transrectal portal scintigraphy. Br J Radiol. Oct 2000;73(874):1115-9. [Medline].

  13. Milot L, Kamaoui I, Gautier G, Pilleul F. Hereditary-hemorrhagic telangiectasia: one-step magnetic resonance examination in evaluation of liver involvement. Gastroenterol Clin Biol. Aug-Sep 2008;32(8-9):677-85. [Medline].

  14. Richards-Yutz J, Grant K, Chao EC, Walther SE, Ganguly A. Update on molecular diagnosis of hereditary hemorrhagic telangiectasia. Hum Genet. Apr 23 2010;[Medline].

  15. Wooderchak W, Gedge F, McDonald M, Krautscheid P, Wang X, Malkiewicz J, et al. Hereditary hemorrhagic telangiectasia: two distinct ENG deletions in one family. Clin Genet. Apr 14 2010;[Medline].

  16. Greve E, Moussata D, Gaudin JL, et al. High diagnostic and clinical impact of small-bowel capsule endoscopy in patients with hereditary hemorrhagic telangiectasia with overt digestive bleeding and/or severe anemia. Gastrointest Endosc. Apr 2010;71(4):760-7. [Medline].

  17. Harries PG, Brockbank MJ, Shakespeare PG, Carruth JA. Treatment of hereditary haemorrhagic telangiectasia by the pulsed dye laser. J Laryngol Otol. Nov 1997;111(11):1038-41. [Medline].

  18. Harrison DF. Use of estrogen in treatment of familial hemorrhagic telangiectasia. Laryngoscope. Mar 1982;92(3):314-20. [Medline].

  19. Buscarini E, Manfredi G, Zambelli A. Bevacizumab to treat complicated liver vascular malformations in hereditary hemorrhagic telangiectasia: a word of caution. Liver Transpl. Nov 2008;14(11):1685-6; author reply 1687-8. [Medline].

  20. Yaniv E, Preis M, Hadar T, Shvero J, Haddad M. Antiestrogen therapy for hereditary hemorrhagic telangiectasia: a double-blind placebo-controlled clinical trial. Laryngoscope. Feb 2009;119(2):284-8. [Medline].

  21. Lebrin F, Srun S, Raymond K, Martin S, van den Brink S, Freitas C, et al. Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat Med. Apr 2010;16(4):420-8. [Medline].

  22. Isaacs E. Aminocaproic Acid. In: Pediatric Drug Dosage Handbook. 8th ed. Ottawa, Canada: Winnipeg Health Sciences Center and CSHP; 1998:161.

Previous
Next
 
Typical symptoms in a patient with Osler-Weber-Rendu syndrome with red nodules and starry telangiectasia on the cheeks.
Close-up view of typical symptoms of patient with Osler-Weber-Rendu syndrome with red nodules and starry telangiectasia on the lips.
Close-up view of typical symptoms in a patient with Osler-Weber-Rendu syndrome with red nodules and starry telangiectasia on the cheeks.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.